J Breast Cancer.  2010 Dec;13(4):392-397. 10.4048/jbc.2010.13.4.392.

Clinicopathological Characteristics and Factors Affecting Recurrence of Ductal Carcinoma In Situ in Korean Women

• Kim JS
• Moon HG
• Ahn SK
• Min JW
• Shin HC
• Kim HS
• Yeom CK
• Ha SH
• Chie EK
• Han W
• Noh DY

• KMID: 2286527
• DOI: http://doi.org/10.4048/jbc.2010.13.4.392

Abstract

PURPOSE
As breast cancer screening becomes more popular in Korea, incidence of ductal carcinoma in situ (DCIS) of breast has increased to more than 10% of all breast cancer diagnosed. We aimed to show the clinicopathological characteristics and factors affecting recurrence of DCIS in Korean women.
METHODS
We retrospectively reviewed 152 DCIS patients who underwent breast conserving surgery in Seoul National University Hospital between January 1995 and December 2005.
RESULTS
Mean age at diagnosis was 46.7 years (24 to 66 years). Mean follow up duration of the patients was 73.82 months (0.80 to 168.43 months). Recurrence of disease occurred in 19 (12.5%) patients: 2 in contralateral breast, 15 in ipsilateral breast, and 2 in axilla. One patient showed ipsilateral breast recur after excision of axillary metastasis. Eight (42.11%) of all recurrence was infiltrating ductal carcinoma and one of them showed bone metastasis during follow up. In an multivariate analysis of factors affecting recurrence, younger age at diagnosis and omission of radiotherapy had significant association with recurrence (p=0.005 and p=0.002, respectively). However, tumor size (p=0.862), microinvasion (p=0.988), histologic grade (p=0.157), estrogen receptor status (p=0.401) and resection margin status (p=0.112) were not significantly correlated with recurrence. There was no breast cancer associated mortality.
CONCLUSION
In this study, we found that the younger age at diagnosis and omission of adjuvant radiotherapy are independent predictors of recurrence in Korean DCIS patients.

Keyword

Age; Breast neoplasms; Ductal carcinoma in situ; Radiotherapy; Recurrence

MeSH Terms

Axilla
Breast
Breast Neoplasms
Carcinoma, Ductal
Carcinoma, Intraductal, Noninfiltrating
Estrogens
Female
Follow-Up Studies
Humans
Incidence
Korea
Mass Screening
Mastectomy, Segmental
Multivariate Analysis
Neoplasm Metastasis
Radiotherapy, Adjuvant
Recurrence
Retrospective Studies
Estrogens

Reference

1. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010. 102:170–178.

2. Frykberg E. An overview of the history and epidemiology of ductal carcinoma in situ of the breast. Breast J. 1997. 3:227–231.

3. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, et al. National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ September 22-24, 2009. J Natl Cancer Inst. 2010. 102:161–169.

4. Ko SS. Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol. 2008. 98:318–323.

5. Sontag L, Axelrod DE. Evaluation of pathways for progression of heterogeneous breast tumors. J Theor Biol. 2005. 232:179–189.

6. Lee HD, Kim DY, Choi JW, Park BW, Jung WH, Oh KK. Clinicopathological analysis of ductal carcinoma in situ (DCIS) and ductal carcinoma in situ with microinvasion. J Korean Surg Soc. 2001. 60:495–500.

7. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009. 27:279–288.

8. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008. 14:370–378.

9. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009. 27:1615–1620.

10. Neuschatz AC, DiPetrillo T, Steinhoff M, Safaii H, Yunes M, Landa M, et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer. 2002. 94:1917–1924.

11. Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer. 2010. 103:94–100.

12. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008. 8:307.

13. Shah DN, Vapiwala N, Solin LJ. Outcomes after breast conservation treatment with radiation in women with ductal carcinoma in situ and prior nonbreast malignancy. Breast J. 2009. 15:649–652.

14. Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg. 2003. 90:426–432.

15. Vicini FA, Recht A. Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol. 2002. 20:2736–2744.

16. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001. 19:2263–2271.

17. Collins LC, Achacoso N, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP Jr, et al. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009. 33:1802–1808.

18. von Smitten K. Margin status after breast-conserving treatment of breast cancer: how much free margin is enough? J Surg Oncol. 2008. 98:585–587.

19. Luini A, Rososchansky J, Gatti G, Zurrida S, Caldarella P, Viale G, et al. The surgical margin status after breast-conserving surgery: discussion of an open issue. Breast Cancer Res Treat. 2009. 113:397–402.

20. Thomas J, Evans A, Macartney J, Pinder SE, Hanby A, Ellis I, et al. Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2,564 cases from the Sloane Project. Br J Cancer. 2010. 102:285–293.

21. Chung YS, Lee YS, Jeh SK, Song BJ, Kim JS, Jeon HM, et al. The role of preoperative magnetic resonance imaging for detecting the extent of disease and predicting the prognosis of ductal carcinoma in situ. J Breast Cancer. 2009. 12:106–112.

22. Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009. 27:5319–5324.

23. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials. Breast. 2009. 18:143–149.

24. Sakorafas GH, Farley DR, Peros G. Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev. 2008. 34:483–497.

25. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001. 345:1378–1387.

26. Moore KH, Sweeney KJ, Wilson ME, Goldberg JI, Buchanan CL, Tan LK, et al. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit. Ann Surg Oncol. 2007. 14:2911–2917.

27. Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg. 2008. 247:315–319.

28. Morrow M. Axillary surgery in DCIS: is less more? Ann Surg Oncol. 2008. 15:2641–2642.

29. Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, et al. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res. 2010. 16:1605–1612.